Physician profile
Amanda Stark
NPI 1316414642
$2,589.10
in general payments reported to CMS, 2019-2025
26 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.55 · 2022: $52.51 · 2023: $532 · 2024: $871 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.04 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $450.94 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $439.04 | 2023-2025 | |
| Pfizer INC. | $326.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $258.54 | 2023-2025 | Airsupra, Farxiga |
| Currax Pharmaceuticals LLC | $242.61 | 2023-2025 | Contrave, Onzetra Xsail, Nexletol |
| Lilly USA, LLC | $189.85 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $172.24 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $112.15 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.57 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $33.87 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $30.10 | 2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $28.34 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.40 | 2023 | Jardiance |
| Lundbeck LLC | $21.87 | 2024 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.87 | 2023 | Veozah |
| Supernus Pharmaceuticals, INC. | $18.57 | 2025 | Qelbree |
| Amgen INC. | $16.58 | 2025 | Krystexxa |
| Seqirus USA INC | $15.79 | 2024 | Flucelvax, Fluad |
| Hologic Sales and Service, LLC | $15.37 | 2024 | Aptima |
| Shield Therapeutics INC | $13.88 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $13.78 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $13.14 | 2024 | Arexvy, Trelegy Ellipta |
| Genentech USA, INC. | $12.55 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.92 | 2022 | |
| Corium, LLC | $9.65 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.